Phase 2 study of oral panobinostat (LBH589) with or without erythropoietin in heavily transfusion-dependent IPSS low or int-1 MDS patients

Leukemia

Volumn 28, Issue 3, 2014, Pages 696-698

  Platzbecker, U ^a   Al Ali, H K ^b   Gattermann, N ^c   Haase, D ^d   Janzen, V ^e   Krauter, J ^f   Gotze K ^g   Schlenk, R ^h   Nolte, F ⁱ   Letsch, A ^j   Ottmann, O G ^k   Kundgen A ^c   Lubbert M ^l   Germing, U ^c   Wermke, M ^a   Reinhard, H ^m   Weiss, C ^m   Lieder, K ^m   Ehninger, G ^a   Leismann, O ^m   Giagounidis, A ⁿ   more..

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^b UNIVERSITY HOSPITAL LEIPZIG   (Germany)

^c UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

^d UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^e UNIVERSITY HOSPITAL BONN   (Germany)

^f HANNOVER MEDICAL SCHOOL   (Germany)

^g TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^h UNIVERSITY HOSPITAL ULM   (Germany)

ⁱ UNIVERSITY OF HEIDELBERG   (Germany)

^j CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^k UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^l UNIVERSITY OF FREIBURG   (Germany)

^m Novartis Pharma GmbH Nürnberg   (Germany)

ⁿ MARIEN HOSPITAL DÜSSELDORF   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ERYTHROPOIETIN; PANOBINOSTAT;

ANEMIA; ANOREXIA; ASTHENIA; DIARRHEA; ERYTHROCYTE TRANSFUSION; FATIGUE; HUMAN; HYPOTHYROIDISM; LETTER; LEUKOPENIA; MYELODYSPLASTIC SYNDROME; NAUSEA; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; THROMBOCYTOPENIA;

ADMINISTRATION, ORAL; BLOOD TRANSFUSION; ERYTHROPOIETIN; HUMANS; HYDROXAMIC ACIDS; INDOLES; MYELODYSPLASTIC SYNDROMES;

EID: 84895817174     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2013.325     Document Type: Letter

References (15)

1. Hellstrom-Lindberg E, Gulbrandsen N, Lindberg G, Ahlgren T, Dahl IM, Dybedal I et al. A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietinþgranulocyte colony-stimulating factor: Significant effects on quality of life. Br J Haematol 2003; 120: 1037-1046.
2. Bejar R, Stevenson K, Abdel-Wahab O, Galili N, Nilsson B, Garcia-Manero G et al. Clinical effect of point mutations in myelodysplastic syndromes. N Engl J Med 2011; 364: 2496-2506.
3. Shih AH, Abdel-Wahab O, Patel JP, Levine RL. The role of mutations in epigenetic regulators in myeloid malignancies. Nat Rev Cancer 2012; 12: 599-612.
4. Kuendgen A, Knipp S, Fox F, Strupp C, Hildebrandt B, Steidl C et al. Results of a phase 2 study of valproic acid alone or in combination with all-Trans retinoic acid in 75 patients with myelodysplastic syndrome and relapsed or refractory acute myeloid leukemia. Ann Hematol 2005; 84(Suppl 1): 61-66.
5. Deangelo DJ, Spencer A, Bhalla KN, Prince HM, Fischer T, Kindler T et al. Phase Ia/II, 2-Arm, open-label, dose-escalation study of oral panobinostat administered via 2 dosing schedules in patients with advanced hematologic malignancies. Leukemia 2013; 27: 1628-1636.
6. Prince HM, Bishton MJ, Johnstone RW. Panobinostat (LBH589): A potent pan-deacetylase inhibitor with promising activity against hematologic and solid tumors. Future Oncol 2009; 5: 601-612.
7. Hellstrom-Lindberg E, Negrin R, Stein R, Krantz S, Lindberg G, Vardiman J et al. Erythroid response to treatment with G-CSF plus erythropoietin for the anaemia of patients with myelodysplastic syndromes: Proposal for a predictive model. Br J Haematol 1997; 99: 344-351.
8. Cheson BD, Greenberg PL, Bennett JM, Lowenberg B, Wijermans PW, Nimer SD et al. Clinical application and proposal for modification of the International Working Group. (IWG) response criteria in myelodysplasia. Blood 2006; 108: 419-425.
9. Itzykson R, Ayari S, Vassilief D, Berger E, Slama B, Vey N et al. Is there a role for alltrans retinoic acid in combination with recombinant erythropoetin in myelodysplastic syndromes?. A report on 59 cases. Leukemia 2009; 23: 673-678.
10. Younes A, Sureda A, Ben-Yehuda D, Zinzani PL, Ong TC, Prince HM et al. Panobinostat in patients with relapsed/refractory Hodgkin's lymphoma after autologous stem-cell transplantation: Results of a phase II study. J Clin Oncol 2012; 30: 2197-2203.
11. Giver CR, Jaye DL, Waller EK, Kaufman JL, Lonial S. Rapid recovery from panobinostat (LBH589)-induced thrombocytopenia in mice involves a rebound effect of bone marrow megakaryocytes. Leukemia 2011; 25: 362-365.
12. Wagner JM, Hackanson B, Lubbert M, Jung M. Histone deacetylase (HDAC) inhibitors in recent clinical trials for cancer therapy. Clin Epigenetics 2010; 1: 117-136.
13. Cashen A, Juckett M, Jumonville A, Litzow M, Flynn PJ, Eckardt J et al. Phase II study of the histone deacetylase inhibitor belinostat (PXD101) for the treatment of myelodysplastic syndrome (MDS). Ann Hematol 2012; 91: 33-38.
14. Soriano AO, Yang H, Faderl S, Estrov Z, Giles F, Ravandi F et al. Safety and clinical activity of the combination of 5-Azacytidine, valproic acid, and all-Trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome. Blood 2007; 110: 2302-2308.
15. Voso MT, Santini V, Finelli C, Musto P, Pogliani E, Angelucci E et al. Valproic acid at therapeutic plasma levels may increase 5-Azacytidine efficacy in higher risk myelodysplastic syndromes. Clin Cancer Res 2009; 15: 5002-5007..